Johnson & Johnson makes name changes to its pharmaceutical and medtech businesses
For more than 135 years, Johnson & Johnson has provided health care products and solutions to people worldwide. Now, with its exclusive focus on healthcare innovation and tackling the toughest health challenges, the Company is updating its brand and uniting both its medtech and pharmaceutical segments under the Johnson & Johnson brand name to demonstrate its collective power in healthcare.
Moving forward, the Company’s two segments will be more connected to the Johnson & Johnson brand. Over time, Janssen, the Company’s pharmaceutical segment, will be named Johnson & Johnson Innovative Medicine, and the medical technology segment will continue to be named Johnson & Johnson MedTech.
Related news and insights
Alfasigma S.p.A , one of Italy's leading pharmaceutical companies, and Intercept Pharmaceuticals, Inc., a leading biopharmaceutical company in rare and serious liver diseases, announced that they have entered into a definitive merger agreement under which Alfasigma has agreed to acquire Intercept for $19.00 per share in cash
Bayer and Hologic, Inc., announced an international partnership to deliver contrast-enhanced-mammography (CEM) solutions to improve the detection of breast cancer in multiple countries across Canada, the European and Asia Pacific regions